Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

IMPORTANCE: The use of prostate-specific antigen (PSA) screening for prostate cancer is controversial because of the risk of overdiagnosis and overtreatment of indolent cancers. Optimal screening strategies are highly sought. OBJECTIVE: To estimate the long-term risk of any prostate cancer and clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Kovac, Evan, Carlsson, Sigrid V., Lilja, Hans, Hugosson, Jonas, Kattan, Michael W., Holmberg, Erik, Stephenson, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991265/
https://www.ncbi.nlm.nih.gov/pubmed/31940039
http://dx.doi.org/10.1001/jamanetworkopen.2019.19284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991265/
https://www.ncbi.nlm.nih.gov/pubmed/31940039
http://dx.doi.org/10.1001/jamanetworkopen.2019.19284

Ejemplares similares